Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020.
Front Oncol. 2022 Sep 14;12:953013. doi: 10.3389/fonc.2022.953013. eCollection 2022.
Front Oncol. 2022.
PMID: 36185300
Free PMC article.
Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors.
Uitdehaag JC, de Roos JA, Prinsen MB, Willemsen-Seegers N, de Vetter JR, Dylus J, van Doornmalen AM, Kooijman J, Sawa M, van Gerwen SJ, de Man J, Buijsman RC, Zaman GJ.
Uitdehaag JC, et al.
Mol Cancer Ther. 2016 Dec;15(12):3097-3109. doi: 10.1158/1535-7163.MCT-16-0403. Epub 2016 Sep 1.
Mol Cancer Ther. 2016.
PMID: 27587489
Item in Clipboard
Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017.
Uitdehaag JCM, Kooijman JJ, de Roos JADM, Prinsen MBW, Dylus J, Willemsen-Seegers N, Kawase Y, Sawa M, de Man J, van Gerwen SJC, Buijsman RC, Zaman GJR.
Uitdehaag JCM, et al. Among authors: kooijman jj.
Mol Cancer Ther. 2019 Feb;18(2):470-481. doi: 10.1158/1535-7163.MCT-18-0877. Epub 2018 Oct 31.
Mol Cancer Ther. 2019.
PMID: 30381447
Item in Clipboard
Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors.
Conlon NT, Kooijman JJ, van Gerwen SJC, Mulder WR, Zaman GJR, Diala I, Eli LD, Lalani AS, Crown J, Collins DM.
Conlon NT, et al. Among authors: kooijman jj.
Br J Cancer. 2021 Mar;124(7):1249-1259. doi: 10.1038/s41416-020-01257-x. Epub 2021 Jan 21.
Br J Cancer. 2021.
PMID: 33473169
Free PMC article.
Item in Clipboard
Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor.
Jang S, Strickland B, Finis L, Kooijman JJ, Melis JJTM, Zaman GJR, Van Tornout J.
Jang S, et al. Among authors: kooijman jj.
Cancer Chemother Pharmacol. 2023 Jun;91(6):491-499. doi: 10.1007/s00280-023-04534-7. Epub 2023 May 6.
Cancer Chemother Pharmacol. 2023.
PMID: 37148323
Free PMC article.
Item in Clipboard
Selective CK1α degraders exert antiproliferative activity against a broad range of human cancer cell lines.
Nishiguchi G, Mascibroda LG, Young SM, Caine EA, Abdelhamed S, Kooijman JJ, Miller DJ, Das S, McGowan K, Mayasundari A, Shi Z, Barajas JM, Hiltenbrand R, Aggarwal A, Chang Y, Mishra V, Narina S, Thomas M, Loughran AJ, Kalathur R, Yu K, Zhou S, Wang X, High AA, Peng J, Pruett-Miller SM, Daniels DL, Urh M, Shelat AA, Mullighan CG, Riching KM, Zaman GJR, Fischer M, Klco JM, Rankovic Z.
Nishiguchi G, et al. Among authors: kooijman jj.
Nat Commun. 2024 Jan 16;15(1):482. doi: 10.1038/s41467-024-44698-1.
Nat Commun. 2024.
PMID: 38228616
Free PMC article.
Item in Clipboard
Multi-omics analyses of MEN1 missense mutations identify disruption of menin-MLL and menin-JunD interactions as critical requirements for molecular pathogenicity.
Dreijerink KMA, Ozyerli-Goknar E, Koidl S, van der Lelij EJ, van den Heuvel P, Kooijman JJ, Biniossek ML, Rodenburg KW, Nizamuddin S, Timmers HTM.
Dreijerink KMA, et al. Among authors: kooijman jj.
Epigenetics Chromatin. 2022 Aug 9;15(1):29. doi: 10.1186/s13072-022-00461-8.
Epigenetics Chromatin. 2022.
PMID: 35941657
Free PMC article.
Item in Clipboard
Cite
Cite